(Q35710136)

9 August 2017

1 reference

title

Pseudomonas immunotherapy: a historical overview (English)

1 reference

9 August 2017

1 reference

Ian Alan Holder

1

1 reference

PubMed ID

15040935

9 August 2017

language of work or name

English

0 references

publication date

1 February 2004

1 reference

9 August 2017

1 reference

9 August 2017

22

1 reference

9 August 2017

7

1 reference

9 August 2017

831-839

1 reference

USE OF VACCINE AND HYPERIMMUNE SERUM FOR PROTECTION AGAINST PSEUDOMONAS SEPTICEMIA

9 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Susceptibility of burned mice to Pseudomonas aeruginosa and protection by vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Immunization Against Pseudomonas aeruginosa: I. Induction of Protection by an Alcohol-Precipitated Fraction from the Slime Layer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Immunological Control of Pseudomonas Infection in Burn Patients: A Clinical Evaluation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Immunization against Pseudomonas in infection after thermal injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Pseudomonas aeruginosa vaccine in cancer patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Controlled prospective trial of Pseudomonas aeruginosa vaccine in children with acute leukemia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Use of a Pseudomonas Aeruginosa vaccine in pateints with acute leukemia and cystic fibrosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

A New Polyvalent Pseudomonas Vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Active and passive immunization with Pseudomonas aeruginosa ribosomal vaccines and antisera in the burned rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Experimental studies of the pathogenesis of infections due to Pseudomonas aeruginosa: immunization using divalent flagella preparations

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Role of pili in the pathogenesis of Pseudomonas aeruginosa burn infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Studies on the ability of alginate to act as a protective immunogen against infection with Pseudomonas aeruginosa in animals

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Protection against mucoid Pseudomonas aeruginosa in rodent models of endobronchial infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Immunotherapeutic potential of monoclonal antibodies against Pseudomonas aeruginosa protein F

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Preservation of pulmonary function by an outer membrane protein F vaccine. A study in rats with chronic pulmonary infection caused by Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Safety and immunogenicity of a Pseudomonas aeruginosa outer membrane protein I vaccine in human volunteers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

A recombinant hybrid outer membrane protein for vaccination against Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Immunization of burn-patients with a Pseudomonas aeruginosa outer membrane protein vaccine elicits antibodies with protective efficacy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Comparison of two immunization schedules for a Pseudomonas aeruginosa outer membrane proteins vaccine in burn patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Combined host and specific anti-Pseudomonas-directed therapy for Pseudomonas aeruginosa infections in burned mice: experimental results and theoretic considerations.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Vaccine efficacies of elastase, exotoxin A, and outer-membrane protein F in preventing chronic pulmonary infection by Pseudomonas aeruginosa in a rat model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Efficacies of alkaline protease, elastase and exotoxin A toxoid vaccines against gut-derived Pseudomonas aeruginosa sepsis in mice

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Protection against Pseudomonas aeruginosa chronic lung infection in mice by genetic immunization against outer membrane protein F (OprF) of P. aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Analysis of immunization with DNA encoding Pseudomonas aeruginosa exotoxin A

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Mice immunized with DNA encoding a modified Pseudomonas aeruginosa exotoxin A develop protective immunity against exotoxin intoxication

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Pharmacokinetics, tolerability, and preliminary efficacy of human anti-Pseudomonas aeruginosa monoclonal antibodies in pneumonia and burn infection patients

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Immunization with a Pseudomonas aeruginosa elastase peptide reduces severity of experimental lung infections due to P. aeruginosa Or Burkholderia cepacia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Type III secretion/intoxication system important in virulence of Pseudomonas aeruginosa infections in burns

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Therapeutic administration of anti-PcrV F(ab')(2) in sepsis associated with Pseudomonas aeruginosa.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Oral pseudomonas aeruginosa immunization enhances survival in mice subsequently burned and infected with P. aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Protection against fatal Pseudomonas aeruginosa pneumonia in mice after nasal immunization with a live, attenuated aroA deletion mutant

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Safety and immunogenicity of an intranasal Pseudomonas aeruginosa hybrid outer membrane protein F-I vaccine in human volunteers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Isolation and characterization of a high-molecular-weight polysaccharide from the slime of Pseudomonas aeruginosa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

Passive protection by antitoxin in experimental Pseudomonas aeruginosa burn infections

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

7 January 2021

Role of Exotoxin and Protease as Possible Virulence Factors in Experimental Infections with Pseudomonas aeruginosa

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

7 January 2021

Protection against experimental Pseudomonas aeruginosa infection in mice by active immunization with exotoxin A toxoids.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

7 January 2021

Flagellar preparations from Pseudomonas aeruginosa: animal protection studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

7 January 2021

Cross-protection by Pseudomonas aeruginosa polysaccharides

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

7 January 2021

Protection against fatal Pseudomonas aeruginosa burn wound sepsis by immunization with lipopolysaccharide and high-molecular-weight polysaccharide

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

7 January 2021

Human immune response to Pseudomonas aeruginosa mucoid exopolysaccharide (alginate) vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2003.11.028

7 January 2021

10.1016/J.VACCINE.2003.11.028

Identifiers

DOI

1 reference

9 August 2017

1 reference

PubMed ID

15040935